Manufacturing, Combination Drugs

AstraZeneca Invests $1.5 Billion to Build New ADC Manufacturing Facility in Singapore

May 21, 2024

This new facility will allow AstraZeneca to offer full manufacturing processing for antibody drug conjugates.

Daiichi Sankyo Invests Roughly $1.08 Billion to Expand German Production and Development Site for ADCs

February 22, 2024

Daiichi Sankyo is investing approximately €1 billiion (US$1.08 billion) to expand its Pfaffenhofen an der Ilm, Germany, site for ADC development and production.

Bristol Myers Squibb and SystImmune Enter Global ADC Collaboration Worth Potentially up to $8.4 Billion

December 19, 2023

Bristol Myers Squibb and SystImmune plan to co-develop and co-commercialize lead ADC candidate for cancer treatment in US.

Exploring the Optimization of Linker Chemistries for ADCs

December 13, 2023

A look at how linker technology for antibody drug conjugates has evolved.

Distinguishing E&L Testing for Combination Products (AAPS PharmSci 360)

November 06, 2023

Dujuan Lu, PhD, global leader—E&L, SGS Health Sciences, talks about the differences in designing E&L testing for combination products vs. conventional pharmaceuticals.

Key E&L Issues to Consider During Formulation (AAPS PharmSci 360)

November 03, 2023

Dujuan Lu, PhD, global leader—E&L, SGS Health Sciences, recommends some key issues that pharma manufacturers should consider when formulating products that require a medical device.

Genentech Forms Collaboration with PeptiDream for Peptide-Radioisotope Drug Conjugates

September 26, 2023

Under a new pact, Genentech and PeptiDream will collaborate to discover and develop novel peptide-radioisotope drug conjugates.

Olon Makes Headway into ADCs Market with New Manufacturing Facility in Italy

May 31, 2023

API supplier Olon has started construction of a new manufacturing facility in Milan, Italy, which will be dedicated to production of cytotoxic payloads and linkers for ADCs.

Guidance on Q13 Continuous Manufacturing of Drug Substances and Drug Products

March 06, 2023

The guidance is intended to build on the existing International Council for Harmonisation (ICH) quality guidance.

Improving the Fate of ADCs

November 02, 2022

Learning from early market failures, the biopharma industry has worked to improve the fate of antibody drug conjugates.